THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ — Amgen (AMGN) announced today that it has entered into an agreement with Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

source https://finance.yahoo.com/news/amgen-acquire-otezla-13-4-103000647.html?.tsrc=rss